SYMBIOTIX BIOTHERAPIES, INC.

Biotech · Private

Purified capsular polysaccharide (PSA) from Bacteroides fragilis, administered orally to induce regulatory T cells and suppress intestinal inflammation

Grants
$4.2M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Novel commensal polysaccharide treats multiple sclerosis through Treg modulation$2,264,726
Federal grantDepartment of Health and Human Services · Phase II · Therapeutics for inflammatory bowel disease from the microbiome$1,973,386
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1684RENOVATE BIOSCIENCES, INC.——
1685CORE BIOTHERAPEUTICS INC——
1686HUMAN CELL CO——
1687SYMBIOTIX BIOTHERAPIES, INC.——
1688AscentX Medical, Inc.—$3.3M
1689Revolve Biotechnologies, Inc.——
1690MPEX PHARMACEUTICALS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 1
  • Platform For Identifying And/or Characterizing Immunomodulatory Agentsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.